Community perks,
exclusive to you

BYTE51 is a Life Science data platform for Founders/Startups to gain access to $702 Billion of Life Science VC Funding data across 6,200 Clinical phases on 22,300 private life science companies funded by 15,200 VC Investors. Secure your lead investor on BYTE51! Nucleate Current Activator discount $65 per month. Nucleate Alumni Activator discount $799 annually. Schedule for a BYTE51 Demo today!

Fenwick is pleased to present the following package to the startups that are part of the Nucleate’s Activator Program (each one, a “Company”), inquire today. 1. Deferral. Fenwick will defer up to $10,000 in fees for legal services until the earlier of (i) when the Company has raised at least $1,000,000 in financing (whether through the sale of equity and/or debt), (ii) the closing of an acquisition of the Company, (iii) 12 months from the date of engagement, or (iv) termination by the Company of Fenwick’s. 2. Board Meetings. We will not charge for our attendance at routine board meetings while the Company is privately held and backed by venture capital or private equity financing. We do charge for travel expenses incurred for non-local meetings that you request we attend in person. 3. Client Intake. We will provide up to 10 hours free new client intake if company already formed. 4. Initial Intellectual Property advice. We will not charge for our time, up to a value of $3k, to provide initial advice on IP issues related to patent filing and prosecution strategy, licensing agreements, IP ownership and assignment, and freedom to operate risk analysis. Additionally, we will offer a further deferral of fees of up to $10k related to drafting and filing the first provisional patent application.

As part of their partnership with Nucleate, Mercury is excited to offer a number of exclusive perks for Nucleate community members to help them hit the ground running, including a $500 sign up bonus, discounts on lab space and other partnered services, and free 409A valuations. Follow this link to learn more about Mercury’s platform, open an account, or connect with their team!

Fedsprout is a premier consulting firm specializing in SBIR/STTR funding, commercialization, and award management for life science startups. They provide expert guidance on securing non-dilutive funding, crafting winning proposals, ensuring compliance with federal regulations, and navigating commercialization pathways within the SBIR/STTR program. With a proven track record of writing hundreds of proposals and supporting awardees, Fedsprout helps innovators bring cutting-edge therapeutics, diagnostics, and medical devices to market seamlessly. As part of this partnership, teams affiliated with Nucleate are eligible for a significant discount on Fedsprout services. To learn more about eligibility and available support, please contact ashah@fedsprout.com.

HiTE™ is a transduction enhancement technology developed by Nucleate alumni, designed to address one of the biggest bottlenecks in cell and gene therapy manufacturing: low and inconsistent viral transduction efficiency. HiTE™ uses a novel class of Transient Fusion-Promoting Peptides (TFPs) to enhance transduction across primary T cells (63%), iPSCs (73.9%), and NK cells (33.3%) representing 4–47× improvements over standard enhancers while maintaining >90% cell viability and enabling a 5–10× reduction in viral vector usage. The technology is drop-in compatible with existing workflows: no spinoculation, no plate coating, and under 8 hours from start to finish. HiTE™ is currently available for research use. Learn more at our website, white paper, or connect on LinkedIn.

Forage Evolution is helping scientists spend less time at the bench and more time on the science—starting with the new Forager-Fast Plasmid Subcloning Kit, just launched by an NY alum–founded team. It’s the first competent cell on the market that does the plasmid transformation for you and grows super fast, so you can get to purified plasmid a full day (or two) sooner with far fewer hands-on steps. Want to try it out? Check it out here, and for the Nucleate community (please keep this to participants and alums so we can keep it active!) use promo code NUCLEATE-10 for 10% off.

As early-stage biotech companies navigate lab setup and operations, access to equipment remains a key factor in managing both costs and timelines.  Wasteless Bio is a marketplace for surplus life science equipment and consumables, designed to provide organizations with access to pre-owned instrumentation through a structured, vetted resale model that aims to address considerations around quality, compliance, and reliability. For more information, visit wasteless.bio or learn more here.

Applications are now open for an Associate to join the bio investing team at Amplify Partners. Following the close of a $200M dedicated digital biology fund, Amplify is doubling down on founders building at the intersection of AI and life sciences. The team is looking for someone with a background in CS, AI, or computational biology who’s excited to go deep on research, build meaningful relationships across the bio x AI ecosystem, and work directly on deals from day one. This SF-based role offers high autonomy and the opportunity to help back the next generation of techbio founders. Interested? Reach out directly to david@amplifypartners.com

Marigold Biosciences is building the AI engine to unlock the full potential of programmable medicine. siRNA-based medicines are safe, clinically proven, and make it possible to design new drugs in days instead of decades. But they currently suffer from a last-mile problem: we can get siRNA to the liver, but it can't reach 95% of the body's tissues. Marigold generates proprietary, large-scale in vivo data and trains AI models to design peptides that deliver RNA to any tissue in the body. We are looking for talented and driven scientists to help build the biological data generation engine that fuels our AI models: designing experimental protocols, identifying tissue and disease targets, and managing internal and external discovery. Ideal candidates should have experience in oligonucleotide delivery, peptide design, or highly multiplexed in vivo screening. Joining offers the chance to build a category-defining platform from the ground up, significant equity ownership, and the autonomy to shape the scientific direction of the company. Roles open include Founding Scientist and Head of Biology.

Almost all animal research is still done by hand, with methods dating to the 1960s, and only about 30% of studies replicate. Olden turns an ordinary cage into an automated platform that captures 20 biomarkers of health continuously and reproducibly. Our technology is used by major academic, government, and industry programs, and our first customer paper passed 100,000 views. Be the first in-house scientist at Olden. You’ll run the animal studies that build and validate entirely new measurements of health, cognition, strength, vision, hearing and more, and turn them into products used by labs worldwide. Why you’ll love this: (1) You build new science, not the same assay for the hundredth time. You design and validate brand-new automated measurements and watch them ship. (2) Your work gets seen. You’ll be an author on the papers it produces, and our science travels (our first customer paper passed 100k views). (3) You grow instead of narrowing. You work across biology, hardware, and AI/computer-vision, side by side with the engineers building the tech. (4) First scientist hire: early, high-ownership, and you shape how Olden does science as it scales. (5) The science you want to do, at 10x speed, without the red tape, grant cycles or the decade-long wait to find out if it mattered. Who it’s for: hands-on mouse experience, a PhD, a finishing PhD or postdoc, or a strong MSc/BSc, in neuroscience, physiology, animal behavior, or a related field, who is rigorous, high-agency, and wants to build. This is an early, intense startup role, not a 9-to-5. On site in South San Francisco, Starting now, Apply today.